Tome S, Lucey M R
Liver Unit, Internal Medicine Department, Complejo Hospitalario Universitario de Santiago de Compostela, Spain.
Aliment Pharmacol Ther. 2004 Apr 1;19(7):707-14. doi: 10.1111/j.1365-2036.2004.01881.x.
Alcoholic liver disease, including acute alcoholic hepatitis and alcoholic cirrhosis, is a major cause of morbidity and mortality in the Western world. Abstinence remains the cornerstone of management of all forms of alcoholic liver disease. Recent research, which has elucidated the mechanisms of alcohol-induced liver injury, offers the prospect of advances in the management of alcoholic liver disease. We review the most recent data on the efficacy of treatment of acute alcoholic injury, including nutritional support, corticosteroids, anti-inflammatory agents and antioxidants, and agents that are directed against the progression to fibrosis, such as colchicines, propylthiouracil and antioxidants. Although these therapies offer a tantalizing glimpse into a future that may include therapies that directly alter the process of injury and repair in the liver, none has been shown consistently to improve the course of alcoholic liver damage. Consequently, liver transplantation remains an ultimate option for selected patients with liver failure due to chronic alcoholic liver damage.
酒精性肝病，包括急性酒精性肝炎和酒精性肝硬化，是西方世界发病和死亡的主要原因。戒酒仍然是所有形式酒精性肝病治疗的基石。最近的研究阐明了酒精性肝损伤的机制，为酒精性肝病的治疗进展带来了希望。我们回顾了关于急性酒精性损伤治疗效果的最新数据，包括营养支持、皮质类固醇、抗炎药和抗氧化剂，以及针对纤维化进展的药物，如秋水仙碱、丙硫氧嘧啶和抗氧化剂。尽管这些疗法让我们看到了未来可能出现直接改变肝脏损伤和修复过程的疗法的诱人前景，但目前还没有一种疗法被证明能持续改善酒精性肝损伤的病程。因此，肝移植仍然是因慢性酒精性肝损伤导致肝衰竭的特定患者的最终选择。
